131I-Iodofalan (Telix Pharmaceuticals)

N/A

Report date: 2026/03/13 20:02:36
NME

Base Information

Drug Name131I-Iodofalan (Telix Pharmaceuticals)
Drug Alias Name4-L-[ 131I] iodo-phenylalanine131I-ACD-101131I-IPA131I-TX-101TLX101 +[9] 
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Iodine > 131I +[4] 
Mechanisms of ActionL-type amino acid transporter 1 inhibitors
TargetsL-type amino acid transporter 1
Therapy Area/IndicationsBreast NeoplasmsGlioblastomaNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsAustraliaAustria +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTherapeia GmbH & Co KG
China Registration ClassN/A

Develop Information

Active CompaniesTelix International Pty LtdTelix Pharmaceuticals (Innovations) Pty LtdTelix Pharmaceuticals Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsBreast NeoplasmsGlioblastoma
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A